How Large Is Pfizer's Biosimilar Opportunity?

Roche recently sued Pfizer , stating that the latter's biosimilar for Herceptin amounts to patent infringement. Roche has nearly $2.5 billion in sales at stake. We believe that these lawsuits are going to be increasingly common as Roche and other companies fiercely defend their biologic sales